John L. Walker, MD   OFFICE LOCATION Cardiology Research Associates (1985-Present) Cardiology Physicians, PA (1976-Present) 873 Sterthaus Ave, Suite 302 Ormond Beach, Florida 32174   TELEPHONE: Office: 386-677-6672 & 386-677-5351 Fax: 386-673-2787   Support Staff: Faye Ouellette, R.N. Dennis Dalton, M.A.

EDUCATION

 

MEDICAL LICENSURE

Florida (ME0022583)
Iowa

 

CERTIFICATION

 

PROFESSIONAL SOCIETIES

 

Fellow – American College of Cardiology
Fellow – Council on Clinical Cardiology
American Heart Association
Florida Medical Association
Volusia County Medical Society

 

HOSPITAL AFFILIATIONS

 

OFFICES HELD

 

PUBLICATIONS

 

1. Walker, J.L., Abboud, F.M., and Mark, A.L.: Preferential Distribution of Inhibitory Cardiac receptors in the Inferior Wall of the Left Ventricle. Clin. Res 25 (3): 261A April, 1977 (abstract)

2. Walker, J.L, Thames, M.D., Abboud, F.M, and Klopfenstein, H.D.: Preferential Distribution of Inhibitory Cardiac Receptors in Left Ventricle of the Dog. AM J Physiol 235 (2): H188. 1978

3. Thamas, M.D., Klopfenstein, H.D., Abboud, F.M., Mark, A.L., and Walker, J.L.: Preferential Distribution Of Inhibitory Cardiac Receptors with Vagal Afferents to the Inferoposterior Wall of the Left Ventricle Activated During Coronary Occlusion in Dog. Circ Res 43 (4): 512. 1978

4. Walker, J.L., Abboud, F.M., and Mark, A.L.: Preferential Distribution of Inhibitory Cardiac Receptors in the Inferior Wall of the left Ventricle. Neural Mechanisms in Cardiac Arrhythmias, Raven Press, New York, 1979

5. Walker, J.L., Abboud, F.M., Mark A.L., and Thamas, M.D: Interaction of Cardiopulmonary and Somatic Reflexes in Humans. JCI 65:1491, 1980

 

RESEARCH ACTIVITY

 

CONGESTIVE HEART FAILURE

Sub-Investigator in (3) clinical trials for SmithKline and French Laboratories: Long and Short-term evaluation protocols for congestive heart failure.

Sub-Investigator for Ciba-Geigy in a clinical trial evaluating an investigational vasodilator in congestive heart failure.

Sub-Investigator for Hoechst-Roussel Pharmaceuticals in a clinical trial evaluating Ramipril in the treatment of congestive heart failure.

Principal Investigator for G.H. Besselaar Associates in (3) clinical trials evaluating Benazepril in the treatment of congestive heart failure.

Sub-Investigator for Bristol-Myers Squibb in (2) clinical trials utilizing Fosinopril and Zofinopril in the treatment of congestive heart failure.

Sub-Investigator for Pfizer in a hemodynamic clinical trial of Amlodipine for congestive heart failure.

Principal Investigator for Otsuka America Pharmaceuticals in the treatment of NYHA Class III-IV congestive heart failure. (VEST)

Sub-Investigator for Pfizer Pharmaceuticals in the treatment of non-ischemic NYHA Class III-IV congestive heart failure. (PRAISE-2)

Principal Investigator for Ciba-Geigy in a clinical trial for morbidity and mortality in congestive heart failure NYHA Class II-IV. (VALHEFT)

Sub-Investigator for Scios in (2) clinical trials utilizing intravenous Natrecor in the treatment of decompensated congestive heart failure.

Principal Investigator for Bristol-Myers Squibb in the treatment of congestive heart failure. (IMPRESS)

Principal Investigator for SmithKline Beecham in a mortality clinical trial of severe congestive heart failure. (COPERNICUS)

Principal Investigator for Eli Lilly, in a morbidity and mortality clinical trail for congestive heart failure. (MOXCON)

Principal Investigator for Bristol-Myers Squibb in a clinical trial evaluating patients with chronic heart failure NYHA Class II-IV. (OVERTURE)

Principal Investigator for SmithKline Beecham in a clinical trial for the treatment of stable NYHA Class II-III congestive heart failure. (ENCOR)

Principal Investigator for Searle Pharmaceutical in a clinical trial for the treatment of heart failure following an acute myocardial infarction. (EPHESUS)

Sub-Investigator for Centocor Phase II clinical trial for the treatment of heart failure Class III or IV evaluating the effects of Infliximab (Remicade) – (ATTACH)

Sub-Investigator for St. Jude Medical in a heart failure Class III or IV ventricular resynchronization therapy randomized trial. (VECTOR)

Sub-Investigator for Myogen in an advanced heart failure Class III or IV placebo-controlled phase III clinical trial. (ESSENTIAL)

Sub-Investigator for Otsuka Maryland Research Institute Incorporated, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized with Worsening Congestive Heart Failure. (EVEREST)

 

LEFT VENTRICULAR DYSFUNCTION

Sub-Investigator for Bristol-Myers Squibb in a mortality clinical trial for patients with ASHD and left ventricular dysfunction. (SWORD)

Principal Investigator for Schering-Plough in a clinical trial of Nitro-Dur in post AMI patients.

Sub-Investigator for Novartis in a clinical trial for treatment of high-risk patients after myocardial infarction. (VALIANT)

 

ACUTE MYOCARDIAL INFARCTION

Sub-Investigator in a clinical trial for intravenous Metoprolol in the treatment of AMI.

Principal Investigator for SmithKline and French Laboratories in a clinical trial of Eminase as thrombolytic treatment of AMI.

Principal Investigator for Bristol-Myers Squibb in a clinical trial of thrombolytic treatment in AMI. (IN-TIME)

Principal Investigator for Genentech, Incorporated and Boehringer Ingelheim, Ltd. in the treatment of AMI with thrombolytic treatment. (ASSENT I)

Sub-Investigator for Bristol-Myer Squibb in the thrombolytic treatment of patients with AMI. (IN-TIME II)

Sub-Investigator for Centocor in a clinical trial for the treatment of AMI. (GUSTO V)

 

ACUTE CORONARY SYNDROME

Sub-Investigator for Hoechst Marion Roussell in the treatment of patients at risk of myocardial necrosis due to acute coronary syndrome. (GUARDIAN)

Sub-Investigator for Searle in the treatment of patients with unstable coronary syndromes. (OPUS-TIMI 16)

Principal Investigator for Rhone-Poulenc Rore Pharmaceutical in the treatment of unstable angina and non-Q-wave MI. (ESSENCE)

Sub-Investigator for Roche Pharmaceuticals in a clinical trial for treatment of patients post acute coronary syndrome. (2nd SYMPHONY)

Sub-Investigator for Bristol Myers Squibb in a clinical trial for treatment of patients post acute coronary syndrome. (PROVE IT)

Sub-Investigator for Aventis open-label enoxaprin versus UFH in subjects who present to the emergency room with ACS. (RESCUE)

Sub-Investigator for AstraZeneca in a 12-Week, Randomized, Open-Label, 3-Arm, Parallel Group, Multicenter, Phase IIIb Study Comparing the Efficacy and Safety of Rosuvastatin 20 mg and 40 mg with that of Atorvastatin 80 mg in Subjects with Acute Coronary Syndromes. (LUNAR)

Sub-Investigator for Eli Lilly in a Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary Intervention/TIMI-38 (TRITON)

 

CARDIAC INTERVENTIONAL STUDIES

Sub-Investigator for Searle in the treatment of patients undergoing PTCA and/or stent procedures. (EXCITE)

 

ISCHEMIC/STABLE ANGINA

Sub-Investigator for PACT in a clinical trial of Nifedipine for the treatment of stable angina pectoris.

Principal Investigator for ICI in a clinical trial of Atenolol for treatment of silent ischemia. (ASSIST)

Principal Investigator for SmithKline and French Laboratories in (2) clinical trials of carvedilol for treatment of stable angina.

Sub-Investigator for National Medical Research in a clinical trial of Monoket vs Procardia in the treatment of stable angina.

Sub-Investigator for ClinTrials in a clinical trial of Cardizem CD in the treatment of stable angina pectoris.

Principal Investigator for Ciba-Geigy in a clinical trial of Transderm-Nitro in the treatment of stable angina pectoris. (TIDES II)

Sub-Investigator for 3M Pharmaceuticals in a clinical trial of Minitran in the treatment of stable angina pectoris.

Principal Investigator for Rhone-Poulenec Rorer in (2) clinical trials evaluating Dilacor in the treatment of stable angina.

Principal Investigator for Zeneca Pharmaceuticals to evaluate exercise tolerance in patients treated for chronic stable angina

Sub-Investigator for Hoechst-Roussel Pharmaceuticals in a clinical trial of Diltiazem in the treatment of chronic stable angina.

Principal Investigator for Bristol-Myers Squibb in an ambulatory myocardial ischemia clinical trial.

Principal Investigator for Bristol-Myers Squibb in a clinical trial of Ifetroban for treatment of chronic stable angina.

Principal Investigator for Parke Davis in the treatment of patients with coronary artery disease, silernt ischemia, and effort-induced angina. (QUASAR)

 

ARRHYTHMIAS

Principal Investigator for Searle in a clinical trial of Bidisomide in the treatment of atrial fibrillation/flutter and paroxysmal supraventricular tachycardia.

Sub-Investigator for Pfizer, Inc. in a clinical trial of intravenous Dofetilide for treatment of acute atrial fibrillation/flutter and paroxysmal supraventricular tachycardia.

Principal Investigator for Proctor & Gamble in the treatment of symptomatic atrial fibrillation/flutter and PSVT. (SVA2)

Sub-Investigator for Pfizer, Inc. in a clinical trial of Dofetilide for treatment of paroxysmal atrial fibrillation/flutter and paroxysmal supraventricular tachycardia.

Principal Investigator for Proctor & Gamble in the treatment of symptomatic atrial fibrillation/flutter and PSVT. (SVA3)

Principal Investigator for SmithKline Beecham in a clinical trial for the treatment of atrial fibrillation and other supraventricular arrhythmias.

Principal Investigator for Proctor & Gamble in the treatment of atrial fibrillation/flutter and PSVT. (SVA4)

Principal Investigator for Knoll Pharmaceutical Company in the prevention of symptomatic recurrences of atrial fibrillation. (RAFT)

Sub-Investigator for Proctor and Gamble in a 12-month clinical trial to evaluate doses of oral Azilimide Dihydrochloride in patients with an ICD for the treatment of ventricular arrythmia. (SHIELD)

Sub-Investigator for Proctor and Gamble, A Multi-Center, Open Label, Follow-Up Study to Assess the Long-Term Safety of 125 mg per day of Oral Azimilide Dihydrochloride in Patients with an ICD. (SHIELD OPEN LABEL)

Sub-Investigator for Proctor and Gamble to assess Azimilide Dihydrochloride for the treatment of atrial fibrillation in patients who require electrical cardioversion, with an open-label follow-up phase to assess the long-term efficacy and safety. (A-COMET I)

Sub-Investigator for Proctor and Gamble to assess Azimilide Dihydrochloride for prophylactic treatment of atrial fibrillation and an open-label follow-up to assess the long-term efficacy and safety. (A-STAR)

Sub-Investigator for Sanofi-Aventis in a Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400mg bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients with Atrial Fibrillation/Atrial Flutter (ATHENA)

 

ANTI-COAGULANT

Principal Investigator for Astra Zeneca in a clinical trial to compare an oral direct thrombin inhibitor to dose-adjusted Coumadin in patients with atrial fibrillation. (SPORTIF V)

Principal-Investigator for Boehringer Ingelheim in a Randomized Evaluation of Long Term Anticoagulant Therapy Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etxilate with Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Prospective, Multi-Centre, Parallel-Group, Non-Inferiority Trial (RELY)

 

ANTI-PLATELET AGGREGATION

Principal Investigator for Bristol-Myers Squibb and Sanofi-Snythelabo, Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events. (ACTIVE)

 

HYPERLIPIDEMIA

Sub-investigator for Sandoz Pharmaceuticals in a clinical trial of Lescol for hyperlipidemia.

Principal Investigator for a Merck Phase IV prospective observational study of Statins in high risk patients.

Sub-investigator for Pfizer in an open-label 8-week treatment clinical trial evaluating Atorvastatin doses in dyslipidemic patients. (AT GOAL)

Principal Investigator for AstraZeneca in a placebo-controlled, phase III, clinical trial in the prevention of cardiovascular events among subjects with low levels of LDL-C and elevated levels of C-Reactive Protein (JUPITER)

 

CLAUDICATION

Principal Investigator for Bristol-Myers Squibb in a clinical trial of Ifetroban in the treatment of claudication.

Principal Investigator for Otsuka Pharmaceuticals in a clinical trial to assess the long-term effects of Pletal versus placebo for patients with intermittent claudication secondary to peripheral arterial disease. (CASTLE)

 

HYPERTENSION

Sub-Investigator for Merck Sharp & Dohme in a clinical trial of Plendil for treatment of uncomplicated essential hypertension.

Sub-Investigator for Sankyo in a clinical trial of Temocapril in the treatment of hypertension.

Principal Investigator for Takeda America in a clinical trial in the treatment of hypertension.

Sub-Investigator for Merck Pharmaceuticals in a clinical trial of Losartan vs Amlodipine in the treatment of mild to moderate hypertension. (ELITE)

Sub-Investigator for Schwarz Pharmaceuticals in a clinical trial of Moexipril in mild-moderate hypertension with impaired renal function.

Sub-Investigator for Bristol Myers Squibb in a clinical trial of Omapatrilat versus Enalapril in mild-moderate/severe hypertension. (OCTAVE)

 

LEFT VENTRICULAR HYPERTROPHY

Sub-Investigator for Norvartis in a multi-center, randomized, Double-Blind parallel group study to evaluate the efficacy of Lotrel and benazepril/hydrochlorothiazide in the regression of left ventricular hypertrophy by magnetic resonance imaging in patients with high risk hypertension. (ALIVE)

Principal Investigator for GlaxoSmithKline in a randomized, double-blind, multi-center study comparing the effects of Carvedilol modified release formulation (COREG) and Atenolol in combination with and compared to an Angiotensin converting enzyme inhibitor (LISINOPRIL) on left ventricular hypertrophy. (CLEVER)

 

PCI STUDIES

Principal Investigator for Schering-Plough in a Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention (TRA)

 

 

 

 

 

Home | About Us | Office Locations | Procedures
Physicians | Prevention | Contact Us

 

 

The material provided on this site is for general information purposes only.
It is not intended to be used as medical advice and does not substitute
for proper consultation with trained medical personnel.